Form 4: Soligenix Director Jerome Zeldis Granted Stock Options

Soligenix, Inc. Director Jerome B. Zeldis was granted 17,647 stock options with an exercise price of $1.70, vesting over one year.

Summary

• Jerome B. Zeldis, a Director of Soligenix, Inc. (SNGX), was granted 17,647 stock options.
• The transaction date for this grant was June 20, 2025.
• Each stock option has an exercise price of $1.70.
• The options will vest ratably on September 20, 2025, December 20, 2025, March 20, 2026, and June 20, 2026.
• The expiration date for these stock options is June 20, 2035.
• Following this transaction, Jerome B. Zeldis beneficially owns 17,647 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options aligns the director's interests with shareholder value, which is generally viewed favorably. However, it is a routine compensation event and not indicative of significant new operational or financial developments.

Positives

• The grant of stock options aligns the interests of Director Jerome B. Zeldis with those of Soligenix shareholders, as the options gain value if the company's stock price increases.
• This is a standard form of compensation for directors, indicating ongoing commitment and incentivization.

Future Outlook

This Form 4 filing does not provide a general future outlook for the company, but it details the future vesting schedule for the granted stock options, which extends through June 2026.

Industry Context

The grant of stock options to directors is a common practice across various industries, including biotechnology, to incentivize long-term performance and align leadership interests with shareholder value. This filing is a routine disclosure of such an event.

Related Party Transactions

• The grant of stock options to Director Jerome B. Zeldis constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options can lead to potential future dilution if exercised, but also serves to align the director's incentives with shareholder returns.
• Director (Jerome B. Zeldis): Receives equity-based compensation, incentivizing long-term performance and commitment to the company.

Next Steps

• The stock options will vest ratably on September 20, 2025, December 20, 2025, March 20, 2026, and June 20, 2026.

Key Dates

Keywords

Soligenix, SNGX, stock option, insider transaction, Form 4, beneficial ownership, director compensation, equity compensation